SciClone shares fall on revenue worries, secondary offering fears (SCLN, ARNA)
SciClone Pharmaceuticals Inc. (SCLN) shares are down more than 7 percent in early trading Wednesday, after analyst Hamed Khorsand at BWS Financial expressed concerns about the company’s unsustainable...
View ArticleSciClone Pharmaceuticals (SCLN) Makes A Profit
Shares in SciClone Pharmaceuticals (SCLN) are up 25% to $4.42, and they should be. The company showed a profit in the last quarter. Revenues for the quarter grew 59% to $22.0 million compared with the...
View ArticleUnusual Number of 52-Week Highs in BioHealth Stocks (BCRX, CRIS, NKTR, OGXI,...
As you will see, there are many new 52-week highs out there in some drug and biotech names…. Some of this is on swine flu news despite a big drop in the stock market today, but here goes: BioCryst...
View ArticleSciClone (SCLN) Ends Cancer Treatment Trials
SciCLone Pharmaceuticals (SCLN) announced the discontinuation of the investigational treatments under its randomized, placebo-controlled, double-blind Phase 2 trial that is evaluating RP101 — a...
View ArticleSciClone Under Investigation For Corrupt Overseas Practices
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) was down 32.48% today, a share value loss of $1.14. This major drop is the result of a recent report in a 10-Q filing yesterday which stated that the...
View Article
More Pages to Explore .....